Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PrEPared to Choose (PtC): An Implementation Study of the Delivery of Cabotegravir Long-acting Injectable Pre-exposure Prophylaxis (PrEP) as an HIV Prevention Product Option Within a PrEP Choice Context in a Real World Setting in Cape Town.

NCT06807736 is registered in ClinicalTrials.gov with Desmond Tutu HIV Foundation as lead sponsor.

NCT NCT06807736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06807736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PrEPared to Choose (PtC): An Implementation Study of the Delivery of Cabotegravir Long-acting Injectable Pre-exposure Prophylaxis (PrEP) as an HIV Prevention Product Option Within a PrEP Choice Context in a Real World Setting in Cape Town.
Lead sponsor
Desmond Tutu HIV Foundation
Phase
Observational
Overall status
Recruiting
Start date
February 13, 2024
Completion date
March 31, 2026
Enrollment
1,800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection, sexual and reproductive health